213 related articles for article (PubMed ID: 19894778)
21. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
22. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
Yu D; Wang D; Zhu FG; Bhagat L; Dai M; Kandimalla ER; Agrawal S
J Med Chem; 2009 Aug; 52(16):5108-14. PubMed ID: 19650625
[TBL] [Abstract][Full Text] [Related]
23. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
Krieg AM
Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
[TBL] [Abstract][Full Text] [Related]
24. Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U; Scheulen ME; von Bergwelt-Baildon MS; Weihrauch MR
Expert Opin Investig Drugs; 2011 Mar; 20(3):361-72. PubMed ID: 21254877
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.
Bai L; Chen W; Chen J; Li W; Zhou L; Niu C; Han W; Cui J
J Transl Med; 2017 Feb; 15(1):51. PubMed ID: 28241765
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
[TBL] [Abstract][Full Text] [Related]
27. Development of TLR9 agonists for cancer therapy.
Krieg AM
J Clin Invest; 2007 May; 117(5):1184-94. PubMed ID: 17476348
[TBL] [Abstract][Full Text] [Related]
28. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
29. TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress.
Mohamed W; Domann E; Chakraborty T; Mannala G; Lips KS; Heiss C; Schnettler R; Alt V
BMC Microbiol; 2016 Oct; 16(1):230. PubMed ID: 27716055
[TBL] [Abstract][Full Text] [Related]
30. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.
Krieg AM
Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597
[TBL] [Abstract][Full Text] [Related]
31. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.
Kline JN; Krieg AM
Drug News Perspect; 2008 Oct; 21(8):434-9. PubMed ID: 19034349
[TBL] [Abstract][Full Text] [Related]
32. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
33. Species-Specific Minimal Sequence Motif for Oligodeoxyribonucleotides Activating Mouse TLR9.
Pohar J; Lainšček D; Fukui R; Yamamoto C; Miyake K; Jerala R; Benčina M
J Immunol; 2015 Nov; 195(9):4396-405. PubMed ID: 26416273
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.
Pohar J; Lainšček D; Kunšek A; Cajnko MM; Jerala R; Benčina M
Sci Rep; 2017 Nov; 7(1):14598. PubMed ID: 29097808
[TBL] [Abstract][Full Text] [Related]
35. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
36. The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.
Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Kusagawa S; Ogura S; Tanaka J; Yoneda M; Yamamoto N; Okano H; Takei Y; Ito M; Kasai C; Inoue H; Takase K
Oncol Rep; 2013 May; 29(5):1737-43. PubMed ID: 23467704
[TBL] [Abstract][Full Text] [Related]
37. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
Li J; Song W; Czerwinski DK; Varghese B; Uematsu S; Akira S; Krieg AM; Levy R
J Immunol; 2007 Aug; 179(4):2493-500. PubMed ID: 17675511
[TBL] [Abstract][Full Text] [Related]
38. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
39. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
40. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas.
Tanaka J; Sugimoto K; Shiraki K; Tameda M; Kusagawa S; Nojiri K; Beppu T; Yoneda K; Yamamoto N; Uchida K; Kojima T; Takei Y
Int J Oncol; 2010 Oct; 37(4):805-14. PubMed ID: 20811701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
